Bilateral RSB vs TEA Epidural Analgesia for Postoperative Pain Control After Open Gastrectomy: A Randomized Controlled Trial

Comparison of Bilateral Rectus Sheath Block and Thoracic Epidural Analgesia for Postoperative Pain Control After Open Gastrectomy

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07634731

Enrollment

Registered

2026-06-09

Start date

2021-10-01

Completion date

2024-12-01

Last updated

2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral Rectus Sheath Block, Thoracic Epidural Analgesia

Brief summary

Patients indicated for elective open gastrectomy were screened, enrolled, and randomised between October 2021 and September 2023. The patients were randomised to either Group A (intervention-continuous bupivacaine) or Group B (control-NaCl saline). The primary outcome measures were the quantity of an opioid analgesic administered during the initial 72 h post-surgery and the level of postoperative pain as indicated by the visual analogue scale (VAS

Interventions

PROCEDUREBilateral Rectus Sheath Block and Thoracic Epidural Analgesia for Postoperative Pain Control After Open Gastrectomy.

The surgical procedure involved an upper middle laparotomy. Prior to the surgery, standard preoperative monitoring was conducted, including venous access placement, pulse oximetry, electrocardiography, and automated non-invasive arterial blood pressure measurement. General anesthesia was administered through both intravenous and endotracheal methods following standard protocols.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* (ASA) Grades I to III. * all adult patients (≥18 years) scheduled for elective open gastrectomy

Exclusion criteria

* those requiring acute gastric surgery, * individuals with known bupivacaine allergies * and patients who declined analgesia via RSB catheters and continuous bupivacaine infusions.

Design outcomes

Primary

Measure	Time frame	Description
Postoperative Pain Assessment	12 weeks	VAS

Secondary

Measure	Time frame	Description
Postoperative Recovery	12 weeks	Postoperative bowel movement
Rescue Pain Management and Analgesia	12 weeks	Use of additional NSAIDs
Postoperative recovery	12 weeks	Postoperative days
Opioids	12 weeks	Use of opioids postoperatively

Countries

Latvia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026